Experience after 100 patients treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy

Königsrainer, Ingmar; Zieker, Derek; Glatzle, Jörg; Lauk, Olivia; Klimek, Julia; Symons, Stephan; Brücher, Björn L.D.M.; Beckert, Stefan; Königsrainer, Alfred

doi:10.3748/wjg.v18.i17.2061

Cited by 10 publications

(5 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…We observed a considerable variety of cytotoxic drugs used for HIPEC in PM from CRC. About 2/3 of protocols used MMC as a monotherapy (50%) [2,9,21,22,23,24,25,26,27,28,29,30,31,32,33,34,35,36,37,38,39,40,41,42,43,44,45,46,47,48,49,50,51,52,53,54,55,56,57,58,59,60,61,62,63,64,65,66,67,68,69,70,71,72,73,74,75,76,77,78,79,80,81,82,83,84,85,86,87,88,89,90,91,92,…”

Section: Resultsmentioning

confidence: 99%

“…In 26% of protocols a dextrose containing solution, a dedicated peritoneal dialysis solution (PDS; 21%) or a crystalloid solution (13%) was employed (Figure 10a). Accounting for different drugs, reporting appeared unequal, since in L-OHP containing protocols information on diluent characteristics was omitted in only 20% of protocols (Figure 10b) [28,72,75,81,82,91,116,130,143,147], predominantly employing dextrose-based solutions (65%) [31,32,33,34,35,54,55,66,76,83,108,111,127,128,129,131,132,133,134,135,136,137,138,140,141,144,145,148,149,150], whereas in MMC-based HIPEC, in 50% of protocols respective information was lacking (Figure 10c) [9,22,24,28,30,34,36,40,41,42,43,44,45,48,49,50,51,54,61,62,63,64,66,70…”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Systematic Review of Variations in Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for Peritoneal Metastasis from Colorectal Cancer

Yurttas¹,

Hoffmann²,

Tolios

et al. 2018

JCM

Self Cite

View full text Add to dashboard Cite

Background: Cytoreductive surgery (CRS), followed by hyperthermic intraperitoneal chemotherapy (HIPEC), combines radical surgery with abdominal heated chemotherapy, constituting a multimodal treatment approach. Since clear standards for HIPEC conduct in colorectal carcinoma (CRC) are lacking, we aimed to provide a comprehensive structured survey. Data sources and study eligibility criteria: A systematic literature search was performed in PubMed, with keywords “HIPEC” and “colorectal cancer”, according to established guidelines. Articles were systematically screened, selecting 87 publications complemented by 48 publications identified through extended search for subsequent synthesis and evaluation, extracting inter alia details on used drugs, dosage, temperature, exposure times, and carrier solutions. Results: Compiled publications contained 171 reports on HIPEC conduct foremost with mitomycin C and oxaliplatin, but also other drugs and drug combinations, comprising at least 60 different procedures. We hence provide an overview of interconnections between HIPEC protocols, used drugs and carrier solutions as well as their volumes. In addition, HIPEC temperatures and dosing benchmarks, as well as an estimate of in vivo resulting drug concentrations are demonstrated. Conclusions and implications: Owing to recent developments, HIPEC conduct and practices need to be reassessed. Unfortunately, imprecise and lacking reporting is frequent, which is why minimal information requirements should be established for HIPEC and the introduction of final drug concentrations for comparability reasons seems sensible.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Systematic Review of Variations in Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for Peritoneal Metastasis from Colorectal Cancer

Yurttas¹,

Hoffmann²,

Tolios

et al. 2018

JCM

Self Cite

View full text Add to dashboard Cite

show abstract

“…Similar results were reported in several other gynecological and nongynecological studies. 10,[38][39][40] Eisenkop et al 10 In the context of a multi-center prospective phase III trial in ovarian cancer patients, Wimberger et al 39 reported that the presence of peritoneal carcinomatosis is associated with low rates of maximum tumor debulking in high-volume centers, but peritoneal carcinomatosis was not an independent prognostic factor for OS.…”

Section: Discussionmentioning

confidence: 98%

Prognostic and Predictive Value of the Peritoneal Cancer Index in Primary Advanced Epithelial Ovarian Cancer Patients After Complete Cytoreductive Surgery: Study of Tumor Bank Ovarian Cancer

et al. 2015

View full text Add to dashboard Cite

show abstract

“…Die operative Therapie orientiert sich an der Resektabilität, die durch den PCI objektiviert werden kann, wobei auch bei einem hohen PCI eine Resektion gemäß CC-Score = 0/1 durch eine CRS erreicht werden kann und ein erhöhter PCI keine Kontraindikation bedeutet [80]. …”

Section: Ovarialkarzinomunclassified

Indikationen und Resultate der Peritonektomie bei nichtkolorektaler Peritonealkarzinose

Rau¹,

Kilian²,

Köhler

et al. 2013

Visc Med

View full text Add to dashboard Cite

Hintergund: In dieser Übersichtsarbeit soil der Stellenwert der zytoreduktiven chirurgischen Therapie (CRS) in Kombination mit einer hyperthermen intraperitonealen Chemotherapie (HIPEC) der Peritonealkarzinose bei nichtkolorektalen Karzinomen dargestellt werden. Hierzu zählen als primäre Tumoren des Peritoneums das Mesotheliom und das Pseudomyxoma peritonei. Zu den wichtigsten sekundären malignen Erkrankungen des Peritoneums zählen die Peritonealkarzinose des Magenkarzinoms, des Pankreaskarzinoms und des Ovarialkarzinoms sowie die Sarkomatose. Methode: Pathologische Besonderheiten der einzelnen Entitäten und Therapieempfehlungen anhand der aktuellen Literatur werden im Einzelnen beschrieben. Ergebnisse: Prinzipiell ist die chirurgische Behandlung der Peritonealkarzinose im Sinne einer CRS in Kombination mit einer HIPEC ein sinnvolles Therapiekonzept - vorausgesetzt, dass eine nahezu komplette Tumorentfernung erzielt werden kann. Schlussfolgerung: Aufgrund der erhöhten Morbidität sollte ein chirurgischer Eingriff gut indiziert sein. Bei ausgewählten Patienten ist eine CRS der Peritonealkarzinose in Kombination mit einer HIPEC ein sinnvolles und lebensverlängerndes Verfahren.

show abstract

Experience after 100 patients treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy

Abstract: Patient selection remains the most important issue. Neither PCI, age nor BMI alone should be an exclusion criterion for this multimodal therapy.

Cited by 10 publications

References 22 publications

Systematic Review of Variations in Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for Peritoneal Metastasis from Colorectal Cancer

Systematic Review of Variations in Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for Peritoneal Metastasis from Colorectal Cancer

Prognostic and Predictive Value of the Peritoneal Cancer Index in Primary Advanced Epithelial Ovarian Cancer Patients After Complete Cytoreductive Surgery: Study of Tumor Bank Ovarian Cancer

Indikationen und Resultate der Peritonektomie bei nichtkolorektaler Peritonealkarzinose

Contact Info

Product

Resources

About